Collaborative Arrangement, Upfront Fee Amount

No definition available.

Name:	cdxs_CollaborativeArrangementUpfrontFeeAmount
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contract With Customer, Liability, Portion Of Retainer Fee

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerLiabilityPortionOfRetainerFee
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contract With Customer, Liability, Retainer Fee

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerLiabilityRetainerFee
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contract With Customer, Liability, Retainer Fee, Creditable Percentage

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerLiabilityRetainerFeeCreditablePercentage
Namespace Prefix:	cdxs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, Liability, Retainer Fee, Non-Creditable Percentage

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerLiabilityRetainerFeeNonCreditablePercentage
Namespace Prefix:	cdxs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract with Customer, Liability, Revenue Recognized, Including Opening Balance

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contract With Customer, Sales Milestone

+ References

No definition available.

+ Details

Name:	cdxs_ContractWithCustomerSalesMilestone
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Equity Securities Without Readily Determinable Fair Value, Shares, Milestone Payments Received

+ References

No definition available.

+ Details

Name:	cdxs_EquitySecuritiesWithoutReadilyDeterminableFairValueSharesMilestonePaymentsReceived
Namespace Prefix:	cdxs_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Program Plans

+ References

No definition available.

+ Details

Name:	cdxs_NumberOfProgramPlans
Namespace Prefix:	cdxs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Related Party Transaction, Milestone Payment Received

+ References

No definition available.

+ Details

Name:	cdxs_RelatedPartyTransactionMilestonePaymentReceived
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Annual Payment

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionAnnualPayment
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Contingent Annual Payments, Term

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionContingentAnnualPaymentsTerm
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Contingent Annual Receivable Increase

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionContingentAnnualReceivableIncrease
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue Recognition, Contingent Receivable

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionContingentReceivable
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Revenue, Number Of Days For Payment

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneRevenueNumberOfDaysForPayment
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Number Of Annual Payment

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionNumberOfAnnualPayment
Namespace Prefix:	cdxs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of collaborative research and development agreement.

+ References

No definition available.

+ Details

Name:	cdxs_TermOfCollaborativeResearchAndDevelopmentAgreement
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares of investment owned.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of gross operating revenue recognized in a nonmonetary transaction.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 845
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482864/845-10-50-1

+ Details

Name:	us-gaap_NonmonetaryTransactionGrossOperatingRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investments classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestonePaymentPerTargetGeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_SitagliptinEnzymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=cdxs_CollaborativeArrangementConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cdxs_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cdxs_EnzymeSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_NestecLtd.NestleHealthSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cdxs_StrategicCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_NestleHealthScienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cdxs_AcquisitionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=cdxs_ComputerEquipmentAndSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_TakedaPharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_UpFrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_MolecularAssembliesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdxs_CommercializationAndEnzymeSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdxs_MasterCollaborationResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=cdxs_SeriesAAndBPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_MAIAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cdxs_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_EnzymeProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Narrative (Details) $ in Thousands	1 Months Ended									3 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($)	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Jun. 30, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	May 31, 2019 USD ($)	Dec. 31, 2015	Feb. 29, 2012	Jun. 30, 2023 USD ($)	Sep. 30, 2022 shares	Dec. 31, 2024 USD ($) payment shares	Dec. 31, 2023 USD ($) payment shares	Dec. 31, 2022 USD ($) payment shares	Mar. 31, 2023 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2020 USD ($)	Mar. 31, 2020 USD ($) plan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied												$ 10,121	$ 17,937
Revenues												59,345	70,143	$ 138,590
Contract liabilities: deferred revenue												450	10,761
Investments in non-marketable securities												0	1,191	5,300
Milestone Payment Per Target Gene
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable																		$ 104,000
Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												36,786	42,906	116,676
Product revenue \| Related Party
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												$ 0	$ 0	$ 514
Sitagliptin Enzyme \| Revenue Benchmark \| Collaborative Arrangement Concentration Risk
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Concentration risk, percentage												12.00%	6.00%	4.00%
Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												$ 22,559	$ 27,237	$ 21,914
Research and development revenue \| Related Party
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												0	0	1,245
Supply Agreement \| Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue													1,300
Enzyme Supply Agreement \| Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues													3,200
Merck \| Sitagliptin Enzyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												2,500
Merck \| Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Term of collaborative research and development agreement								5 years	5 years
Merck \| Supply Agreement \| Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied												7,100	4,400	5,900
Nestec Ltd. (Nestle Health Sciences) \| Strategic Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												0	4,100	7,100
Nestlé Health Science \| Acquisition Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues													5,000
Collaborative arrangement, upfront fee amount	$ 5,000
Novartis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied												1,000	1,100	1,000
Contract liabilities: deferred revenue							$ 5,000
Novartis \| Milestone One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable																$ 4,000
Novartis \| Milestone Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable				$ 5,000
Novartis \| Computer equipment and software
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent annual payments, term							4 years
Contingent annual receivable increase							$ 8,000
Revenue recognition, annual payment												$ 6,000	$ 6,000	$ 6,000
Revenue recognition, number of annual payment \| payment												3	3	3
Roche \| Milestone One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue						$ 800
Number of days for payment						45 days
Roche \| Milestone Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable																	$ 900
Roche \| Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues												$ 6,000
Takeda
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue												0	$ 0
Number of program plans \| plan																		3
Revenue recognized, including opening balance												800	2,000	$ 4,900
Takeda \| Up-front Payment
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue																		$ 8,500
MAI \| Commercialization And Enzyme Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate commercial sales, milestone					$ 5,000
MAI \| Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions												$ 0	$ 0	$ 1,200
MAI \| Series A Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares) \| shares					1,587,050
Investments in non-marketable securities					$ 1,000
MAI \| Series B Preferred Stock \| Related Party
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments received (in shares) \| shares			1,587,049	1,587,049							1,587,049
MAI \| Series A and B Preferred Stock \| Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares) \| shares												0	0	1,587,049
MAI \| Product revenue \| Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions												$ 200	$ 200	$ 500
MAI \| Revenue sharing arrangement \| Commercialization And Enzyme Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue					$ 500
MAI \| Revenue sharing arrangement \| Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions												100
MAI Agreement \| Related Party
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
MAI agreement milestone payment received			$ 1,000	$ 1,000
Pfizer \| Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues										$ 5,000		9,500	2,000
Pfizer \| Enzyme Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied													8,200	$ 75,400
Contract liabilities: deferred revenue												0	9,500
Contract with customer, liability, retainer fee		$ 25,900										$ 25,900	$ 25,900
Contract with customer, liability, retainer fee, creditable percentage		90.00%
Contract with customer, liability, portion of retainer fee		$ 23,300													$ 23,300
Contract with customer, liability, retainer fee, non-creditable percentage												50.00%
Pfizer \| Enzyme Product \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Concentration risk, percentage												0.00%	12.00%	54.00%